CoreAge Rx vs VevaRX
Two GLP-1 providers, one scoreboard. We put CoreAge Rx and VevaRX head-to-head on the published Brief Score — the same six factors, scored the same way.
CoreAge Rx
The verdict
CoreAge Rx takes this head-to-head.
CoreAge Rx scores 94 to 68 on our six-factor Brief Score — CoreAge publishes different starting offers across its pages; the advertised annual rates require a full year paid upfront.
That doesn't make VevaRX a bad call — it's best for readers who want to understand the difference between monthly and quarterly payment commitments. Weigh the six factors below against your own priorities before you decide.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.
Factor by factor
Both providers scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.
Price, coverage & the tracker
| Compare | CoreAge Rx | VevaRX |
|---|---|---|
| Brief Score | 94/100 (A) | 68/100 (C) |
| Semaglutide | From $79/mo Annual offer: 12 months paid upfront, from $948. Main site: from $99/mo; confirm the selected offer. Full price detailsFrom $79/mo on the annual-plan landing offer, based on a 12-month plan paid in full ($948 at that starting rate); main product page separately advertises from $99/mo | Confirm the applicable plan price Public product display: $120 monthly or $267 upfront for three months ($89/month equivalent). Legal page separately lists GLP-1 packages at $199 initially/$299 follow-up. Confirm which agreement applies; plans renew automatically. Full price detailsCompounded semaglutide offered; current applicable plan quote unknown because legal-page package prices differ; public monthly plan $120 or $267 upfront every three months; earlier listing: From $189/mo (compounded) |
| Tirzepatide | From $129/mo Annual offer: 12 months paid upfront, from $1,548. Main site: from $149/mo; confirm the selected offer. Full price detailsFrom $129/mo on the annual-plan landing offer, based on a 12-month plan paid in full ($1,548 at that starting rate); main product page separately advertises from $149/mo | Confirm the applicable plan price Public product display: $189 monthly or $447 upfront for three months ($149/month equivalent). Legal page separately lists GLP-1/GIP packages at $349 initially/$399 follow-up. Confirm which agreement applies; plans renew automatically. Full price detailsCompounded tirzepatide offered; current applicable plan quote unknown because legal-page package prices differ; public monthly plan $189 or $447 upfront every three months; earlier listing: Not disclosed |
| Coverage | US only; restrictions by state, confirmed at intake | FAQ lists thirty-six states; terms describe a fifty-state US-only service scope. Confirm medication-specific eligibility rather than treating the broader statement as guaranteed all-state access. |
| Brand-name access | Not confirmed | The checked weight-loss offers are compounded; comparison with branded drugs does not establish branded prescribing. |
| Oral / sublingual | Injection only | Unconfirmed |
| On the tracker | Stableprice stable | Newnew to the tracker, no prior reading |
CoreAge Rx: The checked annual-plan offer starts at $79/$129 per month on annual prepay; the main product pages still show $99/$149. Confirm the selected offer.
VevaRX: Product displays show $120/$189 monthly or $267/$447 quarterly; legal-page package prices differ. Confirm the applicable plan and state eligibility.
Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.